BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng Y, Li J, Martinka M, Li G. The expression of NAD(P)H:quinone oxidoreductase 1 is increased along with NF-kappaB p105/p50 in human cutaneous melanomas. Oncol Rep. 2010;23:973-979. [PMID: 20204281 DOI: 10.3892/or_00000722] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
Number Citing Articles
1 Karami Madani G, Rad A, Molavi M, Ardalan Khales S, Abbaszadegan MR, Forghanifard MM. Predicting the Correlation of EZH2 and Cancer Stem Cell Markers in Esophageal Squamous Cell Carcinoma. J Gastrointest Canc 2018;49:437-41. [DOI: 10.1007/s12029-017-9985-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
2 Butsri S, Kukongviriyapan V, Senggunprai L, Kongpetch S, Zeekpudsa P, Prawan A. Downregulation of NAD(P)H:quinone oxidoreductase 1 inhibits proliferation, cell cycle and migration of cholangiocarcinoma cells. Oncol Lett 2017;13:4540-8. [PMID: 28599455 DOI: 10.3892/ol.2017.5951] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 3.2] [Reference Citation Analysis]
3 Kasai S, Arakawa N, Okubo A, Shigeeda W, Yasuhira S, Masuda T, Akasaka T, Shibazaki M, Maesawa C. NAD(P)H:Quinone Oxidoreductase-1 Expression Sensitizes Malignant Melanoma Cells to the HSP90 Inhibitor 17-AAG. PLoS One 2016;11:e0153181. [PMID: 27045471 DOI: 10.1371/journal.pone.0153181] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
4 Yang Y, Zhang Y, Wu Q, Cui X, Lin Z, Liu S, Chen L. Clinical implications of high NQO1 expression in breast cancers. J Exp Clin Cancer Res. 2014;33:14. [PMID: 24499631 DOI: 10.1186/1756-9966-33-14] [Cited by in Crossref: 87] [Cited by in F6Publishing: 86] [Article Influence: 10.9] [Reference Citation Analysis]
5 Zhang G, Li G. Novel multiple markers to distinguish melanoma from dysplastic nevi. PLoS One 2012;7:e45037. [PMID: 23028750 DOI: 10.1371/journal.pone.0045037] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 2.6] [Reference Citation Analysis]
6 Li J, Zhang Z, Li G. Patient outcome prediction using multiple biomarkers in human melanoma: A clinicopathological study of 118 cases. Exp Ther Med 2011;2:131-5. [PMID: 22977480 DOI: 10.3892/etm.2010.169] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
7 Jiang ZN, Ahmed SMU, Wang QC, Shi HF, Tang XW. Quinone oxidoreductase 1 is overexpressed in gastric cancer and associated with outcome of adjuvant chemotherapy and survival. World J Gastroenterol 2021; 27(22): 3085-3096 [PMID: 34168410 DOI: 10.3748/wjg.v27.i22.3085] [Reference Citation Analysis]
8 Ji M, Jin A, Sun J, Cui X, Yang Y, Chen L, Lin Z. Clinicopathological implications of NQO1 overexpression in the prognosis of pancreatic adenocarcinoma. Oncol Lett. 2017;13:2996-3002. [PMID: 28521407 DOI: 10.3892/ol.2017.5821] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
9 Kowalczyk P, Kowalczyk MC, Junco JJ, Tolstykh O, Kinjo T, Truong H, Walaszek Z, Hanausek M, Slaga TJ. The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A. Mol Carcinog 2013;52:488-96. [PMID: 22351517 DOI: 10.1002/mc.21883] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
10 Parkinson EI, Hergenrother PJ. Deoxynyboquinones as NQO1-Activated Cancer Therapeutics. Acc Chem Res 2015;48:2715-23. [PMID: 26444384 DOI: 10.1021/acs.accounts.5b00365] [Cited by in Crossref: 53] [Cited by in F6Publishing: 51] [Article Influence: 7.6] [Reference Citation Analysis]